# SCYNEXIS (SCYX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/SCYX
## Company Profile
- Ticker: SCYX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Infectious Disease
## Stock Data
- Close: 5.345 USD
- Market cap: 50644677.9 USD
- Last updated: 2026-09-03
## Business Overview
### Metabolic Kidney-Disease Lead Program
SCYNEXIS is developing SCY-770, an orally administered, selective direct activator of AMPK acquired as PXL-770. The program is being advanced for autosomal dominant polycystic kidney disease, where AMPK activation may address multiple drivers of disease progression.
### Antifungal Franchise
SCY-247 is the company's second-generation fungerp antifungal. It is being developed in oral and intravenous formulations for patients with serious fungal infections, including those with limited treatment options.
### Small-Molecule Development Model
The company combines internally developed anti-infective expertise with acquired clinical assets, concentrating resources on differentiated small molecules with potential applications in both rare disease and hospital-based care.
## Why The Stock Is Moving

As of Sep 3, 2026, SCYX closed up 2.39% at $5.34. No new same-company headline was identified in the current news window.

## Future Catalysts

- Topline Phase 1 data for SCY-770 in the third quarter of 2026.
- Topline Phase 1 data for intravenous SCY-247 in the third quarter of 2026.
- Initiation of a Phase 2 proof-of-concept study of SCY-770 in ADPKD in the fourth quarter of 2026.
- Early efficacy data from the SCY-770 Phase 2 study in the second half of 2027.

## Drug Assets

- PXL-770

## Recent News
- 2026-09-01 12:30 EST — [SCYNEXIS to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/SCYX/scynexis-to-participate-in-upcoming-investor-conferences-58a2984d) — Source: SCYNEXIS
- 2026-08-25 23:06 EST — [SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/SCYX/scynexis-announces-inducement-award-under-nasdaq-listing-rule-5635-c-4-b91ab512) — Source: SCYNEXIS
- 2026-08-10 20:30 EST — [SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/SCYX/scynexis-reports-second-quarter-2026-financial-results-and-provides-corporate-up-ac047d9c) — Source: SCYNEXIS
- 2026-06-30 12:00 EST — [SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)](https://biopharmsignal.com/news/SCYX/scynexis-initiates-phase-1-study-of-scy-770-a-novel-ampk-activator-for-the-treat-9e4687ee) — Source: SCYNEXIS
- 2026-05-22 20:15 EST — [SCYNEXIS Announces One-for-Eight Reverse Stock Split](https://biopharmsignal.com/news/SCYX/scynexis-announces-one-for-eight-reverse-stock-split) — Source: SCYNEXIS